- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07943728
Yangyin Qingfei Decoction for Radiation Pneumonitis Prevention (YARD-01)
A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Yangyin Qingfei Decoction in Preventing Radiation Pneumonitis
This prospective, randomized, controlled, open-label phase II clinical study will enroll patients with thoracic malignancies who are scheduled to receive thoracic radiotherapy and whose baseline chest CT/high-resolution CT (HRCT) shows no active pulmonary disease or prior radiation-induced lung injury that could interfere with the assessment of radiation pneumonitis (RP). Eligible patients will be randomized 1:1 to a treatment group or a control group. The control group will receive standard thoracic radiotherapy and routine supportive care; the treatment group will additionally receive oral Yangyin Qingfei Formula concurrently. Patients will be followed for 12 months after radiotherapy to evaluate the formula's efficacy, safety, and potential clinical translational value in preventing RP.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Yujie Hu, MD
- Telefonnummer: 18368101682
- E-post: huyujie@zjhtcm.com
Studieorter
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310000
- Department of Radiotherapy, The First Affiliated Hospital of Zhejiang Chinese Medical University
-
Kontakt:
- chao chen, MD
- Telefonnummer: 13805788140
- E-post: 20053006@zcmu.edu.cn
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria
- Age 18-80 years.
- A pathologically or cytologically confirmed thoracic malignancy, including lung cancer, esophageal cancer, thymic tumors, or similar tumors.
- Planned thoracic radiotherapy, with lung tissue expected to lie within the radiation field.
- No active pulmonary disease or prior radiation-induced lung injury on baseline chest CT/HRCT that could interfere with RP assessment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Estimated survival of at least 6 months.
- Blood counts: absolute neutrophil count >=3.0 x 10^9/L, platelets >=100 x 10^9/L, and hemoglobin >=90 g/L.
- Biochemistry: total bilirubin, blood urea nitrogen, and creatinine <=1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase <=2 times the ULN.
- Ability to eat normally and take a Chinese herbal decoction; voluntary participation and written informed consent.
Exclusion criteria
- Baseline chest CT/HRCT showing active pulmonary infection, interstitial lung disease, marked pulmonary fibrosis, immunotherapy-related pneumonitis, tumor-related post-obstructive pneumonia, or another pulmonary condition that could interfere with RP assessment.
- Unequivocal tumor progression according to RECIST 1.1, or an investigator's judgment that radiotherapy and follow-up cannot be completed in the near term.
- Severe hepatic, renal, cardiovascular, gastrointestinal, or metabolic disease that could affect the safety or efficacy assessment of the study treatment.
- Pregnancy or breastfeeding, or a severe psychiatric disorder that prevents cooperation with the study.
- Participation in another interventional clinical trial within the previous 3 months.
- Regular use of other Chinese herbal medicines, Chinese patent medicines, or antifibrotic drugs specifically intended to prevent RP.
- Poor adherence, inability to take the herbal decoction regularly, or inability to complete scheduled follow-up.
- Any other condition judged by the investigator to make the patient unsuitable for enrollment.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Yangyin Qingfei Formula plus standard thoracic radiotherapy and routine supportive care
|
Yangyin Qingfei decoction will contain Tai Zi Shen (Pseudostellariae Radix) 15 g, Mai Dong (Ophiopogonis Radix) 15 g, Tian Dong (Asparagi Radix) 15 g, Nan Sha Shen (Adenophorae Radix) 15 g, Bei Sha Shen (Glehniae Radix) 15 g, Huang Qin (Scutellariae Radix) 15 g, and Jiao Shan Zhi (charred Gardeniae Fructus) 9 g. One daily prescription will be administered in two doses, 200 mL per dose. If grade 1 gastrointestinal discomfort or another adverse reaction judged possibly related to the decoction occurs, the dose may be reduced to 100 mL twice daily and restored to 200 mL twice daily after symptoms resolve. For grade 2 adverse reactions, the decoction may be suspended and symptomatic treatment provided; after recovery to grade 0-1, treatment may be resumed, with or without dose reduction, at the investigator's discretion. If a grade >=3 adverse reaction, a serious adverse event, or clinically significant decoction-related intolerance occurs, decoction treatment should be stopped, with the r |
|
Aktiv komparator: Standard thoracic radiotherapy plus routine supportive care
Standard thoracic radiotherapy plus routine supportive care |
The control group will receive standard thoracic radiotherapy and routine supportive care without Yangyin Qingfei decoction. Supportive care includes nutritional support and symptomatic management, such as cough relief, expectoration, relief of wheezing, and anti-infective treatment when necessary. Chemotherapy, targeted therapy, or immunotherapy may be administered during follow-up at the investigator's discretion, under the same principles as in the treatment group. Prophylactic amifostine, nintedanib, or other antifibrotic drugs will not be used routinely, nor will other Chinese herbal medicines, Chinese patent medicines, or health supplements specifically intended to prevent RP be used. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Incidence of grade >=2 RP
Tidsram: 3 months after radiotherapy completion
|
3 months after radiotherapy completion
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: chao chen, MD, The First Affiliated Hospital of Zhejiang Chinese Medical University
Publikationer och användbara länkar
Allmänna publikationer
- Giuranno L, Ient J, De Ruysscher D, Vooijs MA. Radiation-Induced Lung Injury (RILI). Front Oncol. 2019 Sep 6;9:877. doi: 10.3389/fonc.2019.00877. eCollection 2019.
- Hou Z, Dong B, Yao Q, Chen H, Shao Q, Li M, Wang J, Chen K, Zhu Z, Peng F, Wei S, Hu X, Li J, Liu M, Xu B, Zheng S, Bi N, Zheng S, Xu Q, Chen B, Wu C, Li R, Chen W, Liu X, Tian Y, Li X, Guo S, Zhao L, Zhu Y, Cai L, Li Q, Li L, Zhang H, Hu C, Wang L, Li Q, Chen B, Chen M. Pirfenidone for grade 2 and grade 3 radiation-induced lung injury: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2025 Dec;26(12):1552-1562. doi: 10.1016/S1470-2045(25)00515-7. Epub 2025 Nov 6.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2027-KS-133-01
- 2027117845 (Annat bidrag/finansieringsnummer: 2027 Annual Zhejiang Provincial Traditional Chinese Medicine Science and Technology Program)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
De-identified individual participant data will not be publicly released. Data may be available from the principal investigator upon reasonable request with a formal data-use agreement
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .